1-20 of 41
Nizar Bahlis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

Noémie Leblay, Sungwoo Ahn, Rémi Tilmont, Mansour Poorebrahim, Ranjan Maity, Holly Lee, Elie Barakat, Jean-Baptiste Alberge, Sarthak Sinha, Arzina Jaffer, Benjamin G. Barwick, Lawrence H. Boise, Nizar Bahlis, Paola Neri
Journal: Blood
Blood (2024) 143 (1): 42–56.
https://doi.org/10.1182/blood.2023020276
Published: 2024
Includes: Supplemental data
Journal Articles

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Clinical Trials & Observations Brief Report
Sarah Gooding, Naser Ansari-Pour, Fadi Towfic, María Ortiz Estévez, Philip P. Chamberlain, Kao-Tai Tsai, Erin Flynt, Marissa Hirst, Dan Rozelle, Paula Dhiman, Paola Neri, Karthik Ramasamy, Nizar Bahlis, Paresh Vyas, Anjan Thakurta
Journal: Blood
Blood (2021) 137 (2): 232–237.
https://doi.org/10.1182/blood.2020007081
Published: 2021
Includes: Supplemental data
Journal Articles

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Jean-Baptiste Alberge, Sarthak Sinha, BSc, Ranjan Maity, PhD, Arzina Jaffer, Justin Donovan, Madison Kong, Stephane Minvielle, PhD, Paola Neri, MD PhD, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 686.
https://doi.org/10.1182/blood-2019-131981
Published: 2019
Journal Articles

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Paola Neri, MD PhD, Ranjan Maity, PhD, Jean-Baptiste Alberge, Sarthak Sinha, BSc, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, PhD, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 572.
https://doi.org/10.1182/blood-2019-127593
Published: 2019
Journal Articles

Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

Christine I Chen, MD, Nizar Bahlis, MD, Cristina Gasparetto, MD, Sascha A Tuchman, MD, Brea C. Lipe, MD, Muhamed Baljevic, MD, Rami Kotb, MD, Heather J. Sutherland, MD PhD, William I. Bensinger, Michael Sebag, MD PhD, Richard Leblanc, MDFRCPC, Christopher P Venner, MD, Gary J. Schiller, MD, Suzanne Lentzsch, MD PhD, Natalie Scott Callander, MD, Heidi Sheehan, Yi Chai, Kazuharu Kai, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Darrell J White, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 141.
https://doi.org/10.1182/blood-2019-122907
Published: 2019
Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD, Nizar Bahlis, MD, Christopher P. Venner, Arleigh McCurdy, MD, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Darrell J White, MD, Rami Kotb, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Tony Reiman, MD, Fernando Camacho, Julia Dobbin, Molei Fu, Engin Gul, BS, MBA, Donna E Reece, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3121.
https://doi.org/10.1182/blood-2019-124457
Published: 2019
Journal Articles

A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)

Cristina Gasparetto, MD, Gary J. Schiller, MD, Natalie Scott Callander, MD, Suzanne Lentzsch, MD PhD, Sascha A Tuchman, MD, Nizar Bahlis, MD, Darrell J White, MD, Christine I Chen, MD, Heather J. Sutherland, MD PhD, Muhamed Baljevic, MD, Rami Kotb, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Christopher P Venner, MD, William I. Bensinger, Heidi Sheehan, Yi Chai, Kazuharu Kai, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Brea C. Lipe, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3157.
https://doi.org/10.1182/blood-2019-122902
Published: 2019
Journal Articles

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

Darrell J White, MD, Suzanne Lentzsch, MD PhD, Cristina Gasparetto, MD, Nizar Bahlis, MD, Christine I Chen, MD, Brea C. Lipe, MD, Gary J. Schiller, MD, Sascha A Tuchman, MD, Heather J. Sutherland, MD PhD, Rami Kotb, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Christopher P Venner, MD, Natalie Scott Callander, MD, William I. Bensinger, Heidi Sheehan, Yi Chai, Kazuharu Kai, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD, Muhamed Baljevic, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3165.
https://doi.org/10.1182/blood-2019-124370
Published: 2019
Journal Articles

Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have Been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)

Nizar Bahlis, MD, Jeffrey A. Zonder, Susan Wroblewski, PhD, Ming Qi, MD PhD, Thomas Renaud, Carolyn Jackson, Thierry Facon, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1831.
https://doi.org/10.1182/blood-2019-123486
Published: 2019
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Hareth Nahi, MD PhD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Christoph Heuck, Xiang Qin, Dolly A. Parasrampuria, PhD, Ming Qi, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1865.
https://doi.org/10.1182/blood-2019-122765
Published: 2019
Journal Articles

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Jonathan L. Kaufman, MD, Saad Z. Usmani, MD, Jesús San-Miguel, Nizar Bahlis, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jon Ukropec, PhD, Thomas Renaud, Sonali Trivedi, Rachel Kobos, MD, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1866.
https://doi.org/10.1182/blood-2019-123483
Published: 2019
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Nizar Bahlis, MD, Thierry Facon, MD, Saad Z. Usmani, MD, Shaji K. Kumar, MD, Torben Plesner, MD DSc, Robert Z. Orlowski, MD, PhD, Cyrille Touzeau, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Hareth Nahi, MD PhD, Cyrille Hulin, MD, Hang Quach, MBBS, FRACP, FRCPA, MD, Hartmut Goldschmidt, Michael E O'Dwyer, MD, Christopher P Venner, MD, Katja C. Weisel, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jianping Wang, Rian Van Rampelbergh, Jon Ukropec, PhD, Clarissa M. Uhlar, Rachel Kobos, MD, Aurore Perrot
Journal: Blood
Blood (2019) 134 (Supplement_1): 1875.
https://doi.org/10.1182/blood-2019-123426
Published: 2019
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Maria-Victoria Mateos, MD PhD, Saad Z. Usmani, MD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Nizar Bahlis, MD, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Xiang Qin, Dolly A. Parasrampuria, PhD, Christoph Heuck, Ming Qi, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1906.
https://doi.org/10.1182/blood-2019-122501
Published: 2019
Journal Articles

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Sarah Gooding, FRCPath,MRCP,MBBChir, Naser Ansari-Pour, PhD, Fadi Towfic, PhD, Maria Ortiz, Dan Rozelle, PhD, Victoria Zadorozhny, Michael Amatangelo, Erin Flynt, Kao-Tai Tsai, Paola Neri, MD PhD, Nizar Bahlis, MD, Paresh Vyas, MD PhD, Anjan Thakurta
Journal: Blood
Blood (2019) 134 (Supplement_1): 1793.
https://doi.org/10.1182/blood-2019-126828
Published: 2019
Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4742.
https://doi.org/10.1182/blood-2019-124191
Published: 2019
Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 925.
https://doi.org/10.1182/blood-2019-124407
Published: 2019
Journal Articles

Identification of Specificity Groups in Myeloma Patients T Cell Receptor (TCR) Repertoire through Single Cell TCR Sequencing

Paola Neri, MD, Ranjan Maity, PhD, Sylvia McCulloch, MD, Peter Duggan, MD, Victor Jimenez-Zepeda, MD, Jason Tay, MD, Nizar Bahlis, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4459.
https://doi.org/10.1182/blood-2018-99-117482
Published: 2018
Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Thierry Facon, Shaji K. Kumar, MD, Torben Plesner, MD DSc, Robert Z. Orlowski, MD PhD, Philippe Moreau, Nizar Bahlis, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Hareth Nahi, MD PhD, Cyrille Hulin, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Hartmut Goldschmidt, MD, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, MD FRCPC, Katja Weisel, MD, Joseph R. Mace, Tahamtan Ahmadi, Christopher Chiu, PhD, Jianping Wang, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, MD, Ming Qi, MD PhD, Saad Z. Usmani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): LBA-2.
https://doi.org/10.1182/blood-2018-120737
Published: 2018
Journal Articles

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

Cristina J Gasparetto, MD, Suzanne Lentzsch, MD, Gary J. Schiller, MD, William Bensinger, MD, Nizar Bahlis, MD, Heather J. Sutherland, MD PhD, Darrell J. White, MD, Michael Sebag, MD PhD, Rami Kotb, MD, Christopher P. Venner, MD FRCPC, Richard Leblanc, MDFRCPC, Christine I Chen, MD, Aldo Del Col, Jatin J. Shah, MD, Jacqueline Jeha, Jean-Richard Saint-Martin, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Joel G. Turner, PhD, Daniel M Sullivan, MD, Brea Lipe, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 599.
https://doi.org/10.1182/blood-2018-99-117201
Published: 2018
Journal Articles

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Shannon M Matulis, PhD, Vikas A. Gupta, MD PhD, Izabelle Brown, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Paola Neri, MD, Nizar Bahlis, MD, Jonathan L Kaufman, MD, Leonard Heffner, MD, Sagar Lonial, MD, Ajay K Nooka, MDMPH, Lawrence H. Boise, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 952.
https://doi.org/10.1182/blood-2018-99-113504
Published: 2018